

BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS



BIO022G
August 2015

Kim Lawson
Project Analyst

ISBN: 1-62296-134-X



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY BACKGROUND	2
STUDY GOAL AND OBJECTIVES	2
INTENDED AUDIENCE	3
SCOPE OF REPORT	3
METHODOLOGY AND INFORMATION SOURCES	4
COMMERCIAL DRUGS	4
DEVELOPMENTAL DRUGS	4
<i>TABLE A FDA APPROVAL PROCESS FOR NEW DRUGS</i>	5
ANALYST'S CREDENTIALS	5
RELATED BCC RESEARCH REPORTS	6
BCC RESEARCH WEBSITE	6
DISCLAIMER	6
CHAPTER 2 SUMMARY	8
<i>SUMMARY TABLE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2020 (\$ MILLIONS)</i>	10
<i>SUMMARY FIGURE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, 2013-2020 (\$ MILLIONS)</i>	10
CHAPTER 3 OVERVIEW	16
BRIEF HISTORY OF PLANT-DERIVED MEDICINES	17
<i>TABLE 1 KEY DATES IN BOTANICAL MEDICINE</i>	18
<i>TABLE 2 WELL KNOWN PLANT-DERIVED DRUGS</i>	18
OPPORTUNITY LIES BEYOND WHAT IS KNOWN	19
<i>FIGURE 1 TYPE OF NATURAL PRODUCT DRUGS SUBMITTED AS IND APPLICATIONS TO THE FDA, 2008 (% SHARES)</i>	19
GETTING STARTED	22
KEY DRIVERS	23
KEY CHALLENGES	24
U.S. GOVERNMENT INVESTMENT	25
INDUSTRY INVESTMENT	27
<i>TABLE 3 SWOT ANALYSIS OF BOTANICAL DRUG DEVELOPMENT</i>	32
<i>TABLE 4 KEY INVESTMENTS IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS</i>	34
NUTRITION SCIENCE PARTNERS LTD. (NESTLE HEALTH): A CASE STUDY	38
BOTANICAL DRUGS DEFINED	40
UNDERSTANDING THE REGULATORY PROCESS	42
<i>TABLE 5 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY</i>	43
INVESTIGATIONAL NEW DRUG APPLICATIONS	43
CLINICAL TRIALS	44
NEW DRUG APPLICATION	44
THE FIRST AND SECOND APPROVED BOTANICAL	45
VEREGEN (CHINESE GREEN TEA CATECHINS)	45
Advice from FDA Based on Veregen Approval	46
FULYZAQ (CROFELEMER)	47
BOTANICAL CANDIDATES IN THE PIPELINE	48

TOPIC	PAGE NO.
SAMITAL AND PANAX GINSENG	48
TCM-700C	49
FEMARELLE AND BRIZO	50
SHINBARO CAPSULE	51
DANSHEN DRIPPING PILL (CARDIOTONIC PILL)	51
EISO (EAST INDIAN SANDALWOOD OIL)	53
MICROBIO AND WH-1, MB-6, AND OB318	55
<i>TABLE 6 BOTANICAL COMPOSITION OF MENERBA (MF 101)*</i>	56
A GROWING PIPELINE	57
<i>FIGURE 2 TOP THERAPEUTIC AREAS OF FDA DRUG APPROVALS*, 2014 (NO. OF DRUG APPROVALS)</i>	57
<i>FIGURE 3 SNAPSHOT OF U.S. FDA BOTANICAL PIPELINE IN 2012</i>	58
OVERALL PHARMA LANDSCAPE	59
<i>TABLE 7 TOP PHARMA COMPANIES BY SALES, 2014 (\$ BILLIONS)</i>	61
<i>TABLE 8 MAJOR UPCOMING U.S. PATENT EXPIRIES, 2014-2019</i>	62
<i>FIGURE 4 PHARMA DRUG SALES BY REGION, 2014 AND 2019 (% OF MARKET SHARE)</i>	62
MAJOR CLASSES OF PLANT DRUGS	63
Terpenes and Steroids	63
Terpenes	63
Steroids	64
Alkaloids and Glycosides	64
Alkaloids	64
Ergot Alkaloids	65
Morphine Alkaloids	65
Vinca Alkaloids	65
Glycosides	66
Cardiac Glycosides	66
Anthraglycosides	66
Phenols	66
E. Cava Algae	66
Flavonoids	66
Resveratrol	67
Coumarin	67
Catechins	67
Proanthocyanidins	67
INTELLECTUAL PROPERTY	68
PRODUCTION	69
A NEW TYPE OF PRODUCTION: PLANT-MADE DRUGS	71
MOVING PRODUCTION FORWARD	72
ARTEMISININ: A CASE STUDY	75
SUPPLY AND LEGAL ISSUES	76
<i>TABLE 9 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS</i>	77
DRUG DEVELOPMENT AND MANUFACTURE	78
<i>TABLE 10 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES</i>	79
CHAPTER 4 MARKET SEGMENTATION	82
GEOGRAPHIC SEGMENTATION	82

TOPIC	PAGE NO.
SALES OF PLANT-DERIVED DRUGS BY REGION	82
THERAPEUTIC AREA SEGMENTATION	82
NUMBER OF PLANT-DERIVED DRUGS BY THERAPEUTIC AREA	82
<i>TABLE 11 NUMBER OF FDA APPROVED BOTANICAL DRUGS, THROUGH 2020 (NUMBER)</i>	82
<i>FIGURE 5 COMPOSITION OF FDA APPROVED BOTANICAL INDICATIONS FORECAST BY THERAPEUTIC AREA, 2015 AND 2020 (%)</i>	83
VALUE OF PLANT-DERIVED DRUGS BY THERAPEUTIC AREA	84
<i>TABLE 12 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPEUTIC AREA, THROUGH 2020 (\$ MILLIONS)</i>	84
<i>FIGURE 6 RELATIVE VALUE SHARE OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPEUTIC AREA, 2015 AND 2020 (%)</i>	84
CHAPTER 5 THERAPEUTIC AREAS FOR BOTANICAL AND PLANT-DERIVED DRUGS	87
HORMONE THERAPY AND METABOLISM APPLICATIONS	87
<i>TABLE 13 PLANT-DERIVED HORMONE THERAPY AND METABOLISM DRUGS IN LATE STAGE DEVELOPMENT</i>	88
INFECTIOUS DISEASE APPLICATIONS	88
<i>TABLE 14 PLANT-DERIVED INFECTIOUS DISEASE DRUGS IN LATE STAGE DEVELOPMENT</i>	89
PAIN AND CENTRAL NERVOUS SYSTEM DISEASE APPLICATIONS	91
<i>TABLE 15 BRAIN DISORDERS THAT ARE REFRACTORY TO SMALL MOLECULE DRUGS</i>	91
<i>TABLE 16 PLANT-DERIVED PAIN AND CNS DRUGS IN LATE STAGE DEVELOPMENT</i>	92
CARDIOVASCULAR AND METABOLIC DISEASE APPLICATIONS	94
<i>TABLE 17 PLANT-DERIVED CARDIOVASCULAR AND METABOLIC DRUGS IN LATE STAGE DEVELOPMENT</i>	94
RESPIRATORY, INFLAMMATION (BOTH NONRELATED AND RELATED TO ORTHOPEDIC) AND AUTOIMMUNE APPLICATIONS	95
<i>TABLE 18 PLANT-DERIVED RESPIRATORY, INFLAMMATION (BOTH NON-RELATED AND RELATED TO ORTHOPEDIC) AND AUTOIMMUNE DRUGS IN LATE STAGE DEVELOPMENT</i>	95
DERMATOLOGY APPLICATIONS	96
<i>TABLE 19 PLANT-DERIVED DERMATOLOGY/WOUND CARE DRUGS IN LATE STAGE DEVELOPMENT</i>	97
GASTROINTESTINAL APPLICATIONS	97
<i>TABLE 20 PLANT-DERIVED GASTROINTESTINAL DRUGS IN LATE STAGE DEVELOPMENT</i>	98
ONCOLOGY APPLICATIONS	99
<i>TABLE 21 ESTIMATED U.S. CANCER CASES BY GENDER, 2015</i>	99
<i>TABLE 22 PLANT-DERIVED ONCOLOGY DRUGS IN LATE STAGE DEVELOPMENT</i>	102
BOTANICAL DRUGS IN LATE STAGE DEVELOPMENT	108
<i>TABLE 23 BOTANICAL DRUGS IN LATE STAGE DEVELOPMENT WITH POSSIBLE FDA-APPROVED COMMERCIALIZATION, THROUGH 2020</i>	109
CHAPTER 6 COMPANY PROFILES	113
ABBOTT LABORATORIES	113
ACORDA THERAPEUTICS, INC.	113
AMAREX CLINICAL RESEARCH	114
ANALYTICON DISCOVERY GMBH	114
ARTECEF BV	115

TOPIC	PAGE NO.
AVESTHAGEN LTD.	115
BAYER HEALTHCARE PHARMACEUTICALS	116
BEIJING PEKING UNIVERSITY WBL BIOTECH CO. LTD.	117
BIONORICA SE	118
BIONUMERIK PHARMACEUTICALS INC.	118
BOEHRINGER INGELHEIM	119
PHARMATON SA	119
BOTANICAL DRUG CORP.	120
BRISTOL MYERS SQUIBB	121
CARDAX PHARMACEUTICALS	124
CHI-MED	125
CHONG KUN DANG PHARMACEUTICAL CORP.	125
CURAPHARM INC.	126
DONG-A-ST	126
DONGWHA PHARM CO. LTD.	127
EISAI INC.	127
EISAI, INC. U.S.	127
EKOMED LLC	128
ELI LILLY	129
FYTOKEM PRODUCTS INC.	129
GALAPAGOS NV	130
GENSPERA INC.	131
GLAXOSMITHKLINE	131
GLENMARK PHARMACEUTICALS LIMITED	133
GREEN CROSS CORP.	133
GREEN LABORATORIES, LLC	134
GW PHARMACEUTICALS PLC	135
HAMIDA PHARMA INC.	136
HANMI PHARMA CO. LTD.	136
HETEROGENEITY LLC	136
INDENA	137
INDUS BIOTECH	139
IZUN PHARMACEUTICALS CORP.	139
JOHNSON & JOHNSON	140
LANZHOU FOCI PHARMACEUTICALS CO. LTD.	141
LEO PHARMA	141
LUPIN LTD.	142
LUPIN PHARMACEUTICALS INC.	142
MEDIGENE	143
MEDIGENE INC. (U.S. DIVISION)	143
MERCK & CO. INC.	144
MERLION PHARMACEUTICALS	145
MICROBIO CO. LTD.	146
MYCOSYNTHETIX, INC.	147
NAPO PHARMACEUTICALS INC.	147
NOVARTIS INTERNATIONAL AG	148
PFIZER	149

TOPIC	PAGE NO.
THE PHARMACEUTICAL PLANT CO.	151
PHARMANUTRIENTS BOTANICAL CORP.	152
PHYNOVA	152
PHYTOCEUTICA INC.	153
PHYTOMYCO RESEARCH PVT. LTD.	154
PHYTOPHARMACON INC.	155
PIRAMAL PHYTOCARE LTD.	156
PRAIRIE PLANT SYSTEMS INC.	156
PUNISYN PHARMACEUTICALS LTD. (RIMONEST LTD.)	157
PURAPHARM INTERNATIONAL LTD.	157
PURGENESIS TECHNOLOGIES INC.	158
QUERCEGEN PHARMACEUTICALS LLC	158
ROTTAPHARM (MADAUS)	159
SANOFI	160
SCHWABE PHARMACEUTICALS	161
SE-CURE PHARMACEUTICALS LTD.	161
SEQUOIA SCIENCES INC.	162
SUN PHARMACEUTICAL INDUSTRIES LTD.	163
SUN TEN PHARMACEUTICAL CO. LTD.	164
TASLY PHARMACEUTICALS INC.	165
TCM BIOTECH INTERNATIONAL CORP.	166
TFS CORPORATION LTD.	167
VALEANT PHARMACEUTICALS INTERNATIONAL INC.	168
SALIX PHARMACEUTICALS INC.	168
VEDIC LIFESCIENCES PVT. LTD.	169
VIROXIS	170
XIANGXUE PHARMACEUTICALS, CO. LTD.	170
ZHEJIANG KANGLAITE GROUP	171
KANGLAITE USA	171
CHAPTER 7 APPENDIX	173
<i>TABLE 24 PLANT-DERIVED DRUGS: THEIR ORIGIN AND ACTIONS</i>	173
<i>TABLE 25 USEFUL RESOURCES FOR THE BOTANICAL DRUG INDUSTRY</i>	178

LIST OF TABLES

TABLE HEADING	PAGE NO.
TABLE A FDA APPROVAL PROCESS FOR NEW DRUGS	5
SUMMARY TABLE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, THROUGH 2020 (\$ MILLIONS)	10
TABLE 1 KEY DATES IN BOTANICAL MEDICINE	18
TABLE 2 WELL KNOWN PLANT-DERIVED DRUGS	18
TABLE 3 SWOT ANALYSIS OF BOTANICAL DRUG DEVELOPMENT	32
TABLE 4 KEY INVESTMENTS IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS	34
TABLE 5 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY	43
TABLE 6 BOTANICAL COMPOSITION OF MENERBA (MF 101)*	56
TABLE 7 TOP PHARMA COMPANIES BY SALES, 2014 (\$ BILLIONS)	61
TABLE 8 MAJOR UPCOMING U.S. PATENT EXPIRIES, 2014-2019	62
TABLE 9 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANT-BASED MEDICINALS	77
TABLE 10 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES	79
TABLE 11 NUMBER OF FDA APPROVED BOTANICAL DRUGS, THROUGH 2020 (NUMBER)	82
TABLE 12 RELATIVE VALUES OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPEUTIC AREA, THROUGH 2020 (\$ MILLIONS)	84
TABLE 13 PLANT-DERIVED HORMONE THERAPY AND METABOLISM DRUGS IN LATE STAGE DEVELOPMENT	88
TABLE 14 PLANT-DERIVED INFECTIOUS DISEASE DRUGS IN LATE STAGE DEVELOPMENT	89
TABLE 15 BRAIN DISORDERS THAT ARE REFRACTORY TO SMALL MOLECULE DRUGS	91
TABLE 16 PLANT-DERIVED PAIN AND CNS DRUGS IN LATE STAGE DEVELOPMENT	92
TABLE 17 PLANT-DERIVED CARDIOVASCULAR AND METABOLIC DRUGS IN LATE STAGE DEVELOPMENT	94
TABLE 18 PLANT-DERIVED RESPIRATORY, INFLAMMATION (BOTH NON-RELATED AND RELATED TO ORTHOPEDIC) AND AUTOIMMUNE DRUGS IN LATE STAGE DEVELOPMENT	95
TABLE 19 PLANT-DERIVED DERMATOLOGY/WOUND CARE DRUGS IN LATE STAGE DEVELOPMENT	97
TABLE 20 PLANT-DERIVED GASTROINTESTINAL DRUGS IN LATE STAGE DEVELOPMENT	98
TABLE 21 ESTIMATED U.S. CANCER CASES BY GENDER, 2015	99
TABLE 22 PLANT-DERIVED ONCOLOGY DRUGS IN LATE STAGE DEVELOPMENT	102
TABLE 23 BOTANICAL DRUGS IN LATE STAGE DEVELOPMENT WITH POSSIBLE FDA-APPROVED COMMERCIALIZATION, THROUGH 2020	109
TABLE 24 PLANT-DERIVED DRUGS: THEIR ORIGIN AND ACTIONS	173
TABLE 25 USEFUL RESOURCES FOR THE BOTANICAL DRUG INDUSTRY	178

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL FORECAST FOR BOTANICAL* AND PLANT-DERIVED DRUGS, 2013-2020 (\$ MILLIONS)	10
FIGURE 1 TYPE OF NATURAL PRODUCT DRUGS SUBMITTED AS IND APPLICATIONS TO THE FDA, 2008 (% SHARES)	19
FIGURE 2 TOP THERAPEUTIC AREAS OF FDA DRUG APPROVALS*, 2014 (NO. OF DRUG APPROVALS)	57
FIGURE 3 SNAPSHOT OF U.S. FDA BOTANICAL PIPELINE IN 2012	58
FIGURE 4 PHARMA DRUG SALES BY REGION, 2014 AND 2019 (% OF MARKET SHARE)	62
FIGURE 5 COMPOSITION OF FDA APPROVED BOTANICAL INDICATIONS FORECAST BY THERAPEUTIC AREA, 2015 AND 2020 (%)	83
FIGURE 6 RELATIVE VALUE SHARE OF FDA APPROVED BOTANICAL DRUGS FORECAST BY THERAPEUTIC AREA, 2015 AND 2020 (%)	84